Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.
This pharma leader has a history of outperforming during rising interest rates.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.